DPDaily Peptide

MELANOTAN I · DECODED

← Back to Decoded
FDA APPROVED · EPP · SCENESSEMC1R SELECTIVE · TANNINGALL OTHER USE OFF-LABEL

Melanotan I

Decoded · FDA Approved (EPP) · Scenesse · Selective MC1R Agonist

Approved for one of the rarest skin conditions in medicine. Unapproved for everything else. Melanotan I (afamelanotide, brand name Scenesse) is FDA-approved for erythropoietic protoporphyria, a rare genetic disorder causing extreme photosensitivity. That approval is based on real Phase 3 data. Tanning, bodybuilding, and cosmetic use have no approved indication and are operating entirely off-label.

BY THE NUMBERS

13
AMINO ACIDS · FULL LENGTH SYNTHETIC α-MSH ANALOG
2019
YEAR FDA APPROVED SCENESSE FOR EPP
<5,000
ESTIMATED EPP PATIENTS IN US · PREVALENCE 1:75,000–1:200,000
MC1R
PRIMARY RECEPTOR · SELECTIVE AGONIST · EUMELANIN PRODUCTION

HOW IT WORKS

Selective agonist of the melanocortin 1 receptor (MC1R). Activation of MC1R in skin melanocytes stimulates eumelanin production, increasing the photoprotective pigment layer. Negligible activity at MC3R and MC4R, which is why Melanotan I has no meaningful sexual or appetite-related effects. FDA approved as Scenesse (afamelanotide) specifically for erythropoietic protoporphyria (EPP), where the MC1R mechanism is the therapeutic target.

WHERE IT CAME FROM

Melanotan I, also known by the INN name afamelanotide, is a synthetic analog of alpha-melanocyte stimulating hormone (α-MSH), a 13-amino acid peptide that the body produces to regulate skin pigmentation. The drug was developed by the University of Arizona in the late 1980s and early 1990s under the direction of Mac Hadley and Victor Hruby, initially with the goal of creating a tanning agent that could protect skin from UV damage without sun exposure. The research program also produced Melanotan II, a structurally related but distinct compound with a different receptor profile.

The key distinction between Melanotan I and Melanotan II is receptor selectivity. Melanotan I is a selective MC1R agonist. MC1R (melanocortin receptor 1) is the receptor on melanocytes (skin pigment cells) responsible for switching from the production of reddish-yellow pheomelanin to brown-black eumelanin, the protective pigment associated with tanning. Melanotan I does not significantly activate MC3R, MC4R, or other melanocortin receptors, which means it produces pigmentation effects without the sexual arousal, appetite suppression, or other central nervous system effects associated with MC4R activation. Scenesse (afamelanotide) was FDA-approved in 2019 for erythropoietic protoporphyria.

THE STUDIES

2019
FDA Approval: Erythropoietic Protoporphyria (EPP): Erythropoietic protoporphyria is a rare genetic metabolic disorder in which a defect in the heme biosynthesis pathway causes protoporphyrin IX to accumulate in red blood cells and tissues. Protoporphyrin IX is extraordinarily photosensitive, meaning exposure to light (including through windows, in shade, and not just direct sunlight) causes severe, painful burning skin reactions. The condition is debilitating and profoundly limits patients' ability to be outdoors. Phase 3 trials of Scenesse (afamelanotide 16mg implant, administered subcutaneously every two months) showed significant increases in pain-free time in sunlight compared to placebo, with meaningful improvement in patient quality of life. This became the basis for FDA approval.
Earlier
European and Australian approval and tanning trials: Scenesse received European Medicines Agency (EMA) approval in 2014 for EPP, before the US approval. Earlier research conducted primarily in Australia examined afamelanotide as a tanning agent in healthy volunteers and in skin cancer prevention in renal transplant patients. These studies showed reliable skin pigmentation induction. They did not lead to an approved tanning indication; the regulatory pathway focused on EPP because the medical need was clearest and most documentable.
Ongoing
Other rare photosensitivity disorders: Research is ongoing into Melanotan I's potential utility in other rare photosensitivity disorders, including variegate porphyria and solar urticaria. These are investigational uses. No additional approvals have been granted beyond EPP.

WHAT THE STUDIES SHOW

FDA APPROVED (EPP)

  • ▸Pain-free sunlight exposure increased significantly vs. placebo
  • ▸Quality of life improvement in EPP patients
  • ▸MC1R selective: no meaningful MC4R activity
  • ▸Eumelanin production confirmed in human subjects

DEMONSTRATED (TANNING)

  • ▸Skin pigmentation in healthy volunteers (early tanning studies)
  • ▸Protective eumelanin production (physiologically similar to natural UV-tan)
  • ▸No approved tanning indication. These are pre-approval research findings.
  • ▸Cosmetic tanning use is off-label

NOT ESTABLISHED

  • ▸Bodybuilding or muscle definition use: no trial data
  • ▸Anti-aging skin benefit: no controlled evidence
  • ▸Long-term safety beyond the EPP clinical trial population
  • ▸Safety at doses used in grey market tanning (differs from Scenesse implant dosing)

SIDE EFFECTS

FROM CLINICAL TRIALS (EPP)

  • ▸Nausea (most common in trial populations)
  • ▸Injection site reactions at implant site
  • ▸Spontaneous erections (less than Melanotan II; occasional in early studies)
  • ▸Flushing and headache
  • ▸Fatigue

NOTABLE / MONITOR FOR

  • ▸Melanocytic nevi: new or changing moles should be monitored, as with any pigmentation modulator
  • ▸Grey market Melanotan I is not the same as the Scenesse implant. Doses, formulation, and purity differ.
  • ▸Nausea can be significant and dose-dependent
  • ▸Long-term safety at non-EPP doses in healthy people: limited data

REGULATORY STATUS

FDA STATUS
FDA Approved · EPP ONLY · Scenesse (afamelanotide)
PHASE
Approved for EPP · Other indications investigational
PROJECTED NDA
CLINUVEL pursuing additional photosensitivity indications

Afamelanotide (Scenesse) is FDA-approved for erythropoietic protoporphyria and is commercially available through CLINUVEL Pharmaceuticals for that specific indication. A subcutaneous implant delivering 16 mg of afamelanotide every two months is the approved formulation and dose. Grey market versions of Melanotan I (afamelanotide) are different in formulation, route, and dose from the approved product, and are not subject to the same quality controls. Off-label tanning or cosmetic use of any injectable Melanotan I variant is unapproved. The distinction between Melanotan I and Melanotan II matters: they are different compounds with different receptor profiles and different regulatory histories.

PROS & CONS

PROS

  • +FDA-approved with Phase 3 data (EPP). The only melanocortin compound in this series with a controlled human trial record and a regulatory approval.
  • +Selective MC1R agonist: avoids the sexual arousal and CNS effects of MC4R activation
  • +Eumelanin production is physiologically similar to natural UV-protective tanning
  • +Approved formulation (Scenesse) has a well-characterized safety profile
  • +CLINUVEL pursuing additional indications

CONS

  • −Approved only for EPP. All other uses are off-label.
  • −Grey market Melanotan I differs from the Scenesse implant in dose and formulation
  • −Nausea is a real and documented side effect
  • −Melanocytic nevi monitoring is appropriate for any pigmentation modulator
  • −EPP approval does not mean safe or appropriate for cosmetic tanning in healthy individuals

DAILY PEPTIDE VERDICT

RANKING

FDA-Approved Drug. Narrow Indication.

Melanotan I (Scenesse) has an FDA approval based on Phase 3 trial data for erythropoietic protoporphyria. The mechanism — selective MC1R agonism producing eumelanin — is clean and well-characterized. The approval is specific to EPP: that indication, that formulation, that dosing. Tanning and cosmetic use are off-label applications with no equivalent evidence base behind them. The distinction between what the Phase 3 data covers and what grey market use applies it to is worth understanding clearly.

Also in MELANOCORTIN (TANNING / LIBIDO)

// MELANOCORTIN (TANNING / LIBIDO)

Melanotan II

GREY MARKETPHASE 1

DISCLAIMER · EDUCATIONAL USE ONLY

This document is for educational and informational purposes only. Melanotan I is an FDA-approved pharmaceutical. Prescribing, dosing, and clinical application are the purview of a licensed healthcare provider. Information here synthesizes publicly available clinical data and does not constitute medical advice.